Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for central nervous system disorders. Its key product, OLINVYK, is an FDA-approved intravenous opioid for acute pain management. The company also develops proprietary pipeline candidates targeting pain, epilepsy, and inflammatory diseases, leveraging innovative mechanisms and patent protections to address significant unmet medical needs in CNS therapeutics.
This description was generated via AI from an annual report. Updated about 1 year ago.